c-MET Pathway and its Inhibitors in Non-Small Cell Lung Cancer: Current Situation and Challenges

c-MET Pathway and its Inhibitors in Non-Small Cell Lung Cancer: Current Situation and Challenges

c-mesenchymal-epithelial transition (c-MET), a novel anti-tumor therapeutic target, is a receptor tyrosin kinase (RTK) that is normally activated by dimerization and transphosphorylation induced by its only ligand, hypatocyte growth factor (HGF). As a complicated and uniquesignaling pathway, c-MET p...

Full description

Bibliographic Details
Main Authors: Fei YAN, Shao-rong YU, Ji-feng FENG
Format: Article
Language:English
Published: Third Party Medicine International Publishing Group Co. Limited 2017-09-01
Series:Journal of International Translational Medicine
Subjects:
c-mesenchymal-epithelial transition
Signaling pathway
Inhibitors
Non-small cell lung cancerFund:This study was approved by National Natural Science Foundation of China: Study on the mechanism of LXR agonist reversing secondary resistance of lung cancer cells to EGFRTKI (No.: H1609).
Online Access:http://www.jitm.hk/EN/abstract/abstract253.shtml

Internet

http://www.jitm.hk/EN/abstract/abstract253.shtml

Similar Items